Chinese Journal of Tissue Engineering Research ›› 2010, Vol. 14 ›› Issue (23): 4329-4342.doi: 10.3969/j.issn.1673-8225.2010.23.033

Previous Articles     Next Articles

Bone marrow mesenchymal stem cells transplantation for kidney diseases  

Zhao Hong-mei1, Hu Xiang2, Li Fang1, Jia Dan-bing1   

  1. 1Department of Nephrology, the 211 Hospital of Chinese PLA, Harbin   150086, Heilongjiang Province, China;
    2Shenzhen Beike Cells Engineering Research Institute, Shenzhen  518057, Guangdong Province, China
  • Online:2010-06-04 Published:2010-06-04
  • Contact: Li Fang, Doctor, Chief physician, Department of Nephrology, the 211 Hospital of Chinese PLA, Harbin 150086, Heilongjiang Province, China weizhaohongmei@ 163.com
  • About author:Zhao Hong-mei, Master, Attending physician, Department of Nephrology, the 211 Hospital of Chinese PLA, Harbin 150086, Heilongjiang Province, China

Abstract:

BACKGROUND: Previous research has proved that bone marrow mesenchymal stem cells (MSCs) transplantation can repair injured kidney and the transplanted MSCs can differentiate into renal tubular epithelial cells, and thereby recovere the structure and function of kidney.

OBJECTIVE: To analyze the application and the potential mechanisms of MSCs for treating kidney disease.

METHODS: A computer-based search of Chinese and English Scientific and Technological Periodical Databases was performed to identify the articles about the correlation between MSCs and kidney disease, with the key words of “bone marrow mesenchymal stem cells, kidney disease”, and the language was limited to Chinese and English. After the first round of selection, the quotations of each literature were also reviewed, and those related to MSC transplantation and kidney disease and published in authoritative journals within 5 years were included. But repetitive articles and Meta analysis were excluded.

RESULTS AND CONCLUSION: Transplantation of MSCs could promote the recovery of renal function by differentiating into glomerulus and tubular cells and it could also promote renal secretion. However, MSC transplantation for treating kidney disease still stayed at clinical test level, and animal models were the major research subjects. Moreover, clinical application for treating IgA kidney disease and secondary kidney disease, such as lupus nephritis, renal amyloidosis, and metastatic renal cell carcinoma, needs to be further studied.

CLC Number: